loading page

Potential targets and plausible drugs of Coronavirus infection caused by 2019-nCoV
  • Faezeh Almasi,
  • Fatemeh Mohammadipanah
Faezeh Almasi

Corresponding Author:[email protected]

Author Profile
Fatemeh Mohammadipanah
Author Profile


The world is confronting a dire situation due to the recent pandemic of the novel coronavirus disease (2019-nCoV) with so far mortality cases of 100,000 all over the world. Currently, there are no effective enough treatment options for this previously unknown virus. The current drugs in pipline and some plausible drug are overviewed in this paper. The potential molecular targets of each steps of the 2019-nCoV drug life cycle is discussed and highlights here. Although different types of anti-viral targets are applicable for 2019-nCoV drug screenings, the more promising targets can be considered as protease and RNA polymerase. Based on the results from antiviral agents repurposing and clinical studies, the remdesivir could be an encouraging drug in the frontline to be administrated for 2019-nCoV. Much progress in understanding the 2019-nCoV the molecular details of its life cycle followed by the identification of therapeutic targets seems to be an efficient approach in discovering potential drugs.
21 Apr 2020Submitted to Transboundary and Emerging Diseases
23 Apr 2020Submission Checks Completed
23 Apr 2020Assigned to Editor
25 Apr 2020Review(s) Completed, Editorial Evaluation Pending
25 Apr 2020Editorial Decision: Revise Major
26 Apr 20201st Revision Received
28 Apr 2020Submission Checks Completed
28 Apr 2020Assigned to Editor
06 May 2020Reviewer(s) Assigned
05 Jun 2020Review(s) Completed, Editorial Evaluation Pending
21 Jun 2020Editorial Decision: Revise Major
27 Jun 20202nd Revision Received
29 Jun 2020Submission Checks Completed
29 Jun 2020Assigned to Editor
01 Jul 2020Reviewer(s) Assigned
05 Jul 2020Review(s) Completed, Editorial Evaluation Pending
07 Jul 2020Editorial Decision: Revise Minor
07 Jul 20203rd Revision Received
09 Jul 2020Submission Checks Completed
09 Jul 2020Assigned to Editor
10 Jul 2020Review(s) Completed, Editorial Evaluation Pending
10 Jul 2020Editorial Decision: Accept